Lineage Cell Therapeutics Inc’s recent filing unveils that its Chief Financial Officer Howe Jill Ann acquired Company’s shares for reported $8850.0 on Nov 26 ’24. In the deal valued at $0.59 per share,15,000 shares were bought. As a result of this transaction, Howe Jill Ann now holds 25,500 shares worth roughly $15300.0.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Samuel George A. III bought 15,000 shares, generating $9,000 in total proceeds. Upon buying the shares at $0.60, the General Counsel now owns 22,184 shares.
Before that, Mulroy Michael H. bought 40,000 shares. Lineage Cell Therapeutics Inc shares valued at $22,640 were divested by the Director at a price of $0.57 per share. As a result of the transaction, Mulroy Michael H. now holds 298,555 shares, worth roughly $0.18 million.
Craig Hallum initiated its Lineage Cell Therapeutics Inc [LCTX] rating to a Buy in a research note published on August 20, 2024; the price target was $4. A number of analysts have revised their coverage, including Robert W. Baird’s analysts, who began to cover the stock in early November with a ‘”an Outperform”‘ rating. B. Riley Securities began covering LCTX with “Buy” recommendation on June 14, 2022. Noble Capital Markets started covering the stock on August 19, 2021. It rated LCTX as “an Outperform”.
Price Performance Review of LCTX
On Monday, Lineage Cell Therapeutics Inc [AMEX:LCTX] saw its stock jump 2.30% to $0.60. Over the last five days, the stock has gained 1.82%. Lineage Cell Therapeutics Inc shares have fallen nearly -45.02% since the year began. Nevertheless, the stocks have fallen -43.99% over the past one year. While a 52-week high of $1.61 was reached on 03/28/24, a 52-week low of $0.50 was recorded on 11/22/24. SMA at 50 days reached $0.8000, while 200 days put it at $0.9850.
Levels Of Support And Resistance For LCTX Stock
The 24-hour chart illustrates a support level at 0.5779, which if violated will result in even more drops to 0.5566. On the upside, there is a resistance level at 0.6177. A further resistance level may holdings at 0.6362. The Relative Strength Index (RSI) on the 14-day chart is 40.05, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0133, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 75.97%. Stochastics %K at 20.12% indicates the stock is a holding.
How much short interest is there in Lineage Cell Therapeutics Inc?
A steep rise in short interest was recorded in Lineage Cell Therapeutics Inc stocks on 2024-10-31, growing by 0.72 million shares to a total of 15.94 million shares. Yahoo Finance data shows the prior-month short interest on 2024-09-30 was 15.22 million shares. There was a rise of 4.5%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on March 31, 2021 when Cantor Fitzgerald began covering the stock and recommended ‘”an Overweight”‘ rating along with a $6 price target.
